Using Genome-wide DNA Methylome Profiling to Analyze Cisplatin-resistance in Human Ovarian Cancers

Dr Chan, David Wai   (Project Coordinator (PC))

Mr Li Benjamin   (Co-Investigator)

Professor Ngan Hextan Yuen Sheung   (Co-Investigator)

Dr Lam Wai Yip   (Co-Investigator)

26

2019-07-01

2021-08-31

3725364

Using Genome-wide DNA Methylome Profiling to Analyze Cisplatin-resistance in Human Ovarian Cancers

Cisplatin-resistance, Genome-wide DNA Methylome, Human Ovarian Cancers

Others - Medicine, Dentistry and Health

UIM/367

Matching Grant for Joint Research

2018

Completed

Ovarian cancer is one of the most lethal gynecological malignancies for female. The high mortality rate of this disease is due to its poor prognosis and most patients present at an advanced stage accompanied by metastasis. The frequent tumor recurrence rate associated with metastasis and chemoresistance are the major obstacles to the clinical management of this disease. Different from other solid tumors, ovarian cancer prefers transcoelomic metastasis and mounting clinical evidence has suggested ovarian cancer patients who have peritoneal metastases are usually poor prognosis and highly chemoresistant recurrence. Rigorous genomic evidence indicates there is a relatively lower frequency of somatic mutations observed in metastatic ovarian cancer cells, suggesting the cancer epigenome plays another important modulator in mediating metastatic progression and chemoresistance of ovarian cancer. Moreover, some ovarian cancer subtypes show different incidence and treatment responses between Asian and Caucasian, indicating the genetic background may contribute to these differences. Therefore, in this study, we proposed to establish a methylome database for Asian ovarian cancer patients, and the systematic examination of genomic DNA methylation status and/or specific gene promoters could also assist in exploring target therapies in ovarian cancers.